Hepalatide - Shanghai HEP Pharmaceutical
Alternative Names: L 47Latest Information Update: 30 Jul 2024
At a glance
- Originator Shanghai HEP Pharmaceutical
- Class Antihyperglycaemics; Antivirals; Peptides
- Mechanism of Action Sodium-bile acid cotransporter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
- Preclinical Diabetes mellitus
Most Recent Events
- 24 Jun 2024 Shanghai HEP Pharmaceutical completes the phase II trial in Hepatitis B (Combination therapy, Treatment-experienced) in China (SC) (NCT05244057)
- 01 Feb 2024 Shanghai HEP Pharmaceutical completes a phase IIa trials in Hepatitis D in China, Mongolia (SC) (NCT05827146)
- 08 Dec 2023 Shanghai HEP Pharmaceutical withdraws a phase I/II trial prior to enrolment in Diabetes mellitus (SC) due to the reason that the study was not approved by CFDA(NCT04662164)